Posted On: 07/21/2016 1:15:10 PM
Post# of 72447
Well, to be a bit more accurate, they do have one approved drug that is producing revenue.
"AMITIZA (lubiprostone)
This discovery resulted in approvals of lubiprostone for treatment of chronic constipation, chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation (IBS-C) in adult women and opioid-induced constipation (OIC) in adults with chronic non-cancer pain (click on the region to review the prescribing information for the approved indication)."
"Pharmaceuticals SCMP reported earnings of 43 cents per share in the fourth quarter of 2015, beating the Zacks Consensus Estimate of 20 cents. Reported earnings also surged from the year-ago figure of 21 cents.
Total revenue was $55.4 million, up 46.6% from the year-ago quarter and ahead of the Zacks Consensus Estimate of $41 million."
http://m.nasdaq.com/article/sucampo-beats-ear...s-cm590509
"AMITIZA (lubiprostone)
This discovery resulted in approvals of lubiprostone for treatment of chronic constipation, chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation (IBS-C) in adult women and opioid-induced constipation (OIC) in adults with chronic non-cancer pain (click on the region to review the prescribing information for the approved indication)."
"Pharmaceuticals SCMP reported earnings of 43 cents per share in the fourth quarter of 2015, beating the Zacks Consensus Estimate of 20 cents. Reported earnings also surged from the year-ago figure of 21 cents.
Total revenue was $55.4 million, up 46.6% from the year-ago quarter and ahead of the Zacks Consensus Estimate of $41 million."
http://m.nasdaq.com/article/sucampo-beats-ear...s-cm590509
(0)
(0)
